TERT and hepatocellular carcinoma: Nevertheless, targeted therapies for HCC encounter considerable hurdles owing to prevalent mutations, including those in the TERT promoter and TP53, which complicate therapeutic targeting (Zheng C. et al., 2023; Wang et al., 2018).